Sertraline for the treatment of depression in alzheimer disease

American Journal of Geriatric Psychiatry

Volumn 18, Issue 2, 2010, Pages 136-145

  Rosenberg, Paul B ^a,c   Drye, Lea T ⁱ   Martin, Barbara K ^b   Frangakis, Constantine ^b   Mintzer, Jacobo E ^d,e   Weintraub, Daniel ^f   Porsteinsson, Anton P ^g   Schneider, Lon S ^h   Rabins, Peter V ^a,b   Munro, Cynthia A ^a   Meinert, Curtis L ^b   Lyketsos, Constantine G ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^d RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ NONE

Author keywords

Alzheimer disease; Antidepressants; Mood disorders; Treatment

Indexed keywords

SERTRALINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INDIGESTION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; TREMOR; XEROSTOMIA;

EID: 75149125207     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e3181c796eb     Document Type: Article

References (34)

1. Jonsson L, Eriksdotter Jonhagen M, et al: Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21:449-459
2. Steinberg M, Shao H, Zandi P, et al: Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2008; 23:170-177
3. Lyketsos CG, Sheppard JM, Steinberg M, et al: Neuropsychiat-ric disturbance in Alzheimer's disease clusters into three groups: the Cache County Study. Int J Geriatr Psychiatry 2001; 16:1043-1053
4. Olin JT, Schneider LS, Katz IR, et al: Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry 2002; 10:125-128
5. Olin JT, Katz IR, Meyers BS, et al: Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry 2002; 10:129-141
6. Lyketsos CG, Olin J: Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry 2002; 52:243-252
7. Rosenberg PB, Onyike CU, Katz IR, et al: Clinical application of operationalized criteria for 'depression of Alzheimer's disease.' Int J Geriatr Psychiatry 2005; 20:119-127
8. Garre-Olmo J, Lopez-Pousa S, Vilalta-Franch J, et al: Evolution of depressive symptoms in Alzheimer disease: one-year follow-up. Alzheimer Dis Assoc Disord 2003; 17:77-85
9. Steinberg M, Tschanz JT, Corcoran C, et al: The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2004; 19:19-26 (Pubitemid 38180688)
10. Kessing LV, Harhoff M, Andersen PK: Treatment with antidepres-sants in patients with dementia-a nationwide register-based study. Int Psychogeriatr 2007; 19:902-913
11. Reifler BV, Teri L, Raskind M, et al: Double-blind trial of imipra-mine in Alzheimer's disease patients with and without depression. Am J Psychiatry 1989; 146:45-49 (Pubitemid 19033221)
12. Nyth AL, Gottfries CG: The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990; 157:894-901
13. Magai C, Kennedy G, Cohen CI, et al: A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry 2000; 8:66-74
14. Petracca GM, Chemerinski E, Starkstein SE: A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 2001; 13:233-240
15. Petracca G, Teson A, Chemerinski E, et al: A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1996; 8:270-275
16. Roth M, Mountjoy CQ, Amrein R: Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry 1996; 168:149-157
17. Lyketsos CG, Sheppard JM, Steele CD, et al: Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's Disease Study. Am J Psychiatry 2000; 157:1686-1689
18. Lyketsos CG, DelCampo L, Steinberg M, et al: Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003; 60:737-746
19. Teri L: Behavior and caregiver burden: behavioral problems in patients with Alzheimer disease and its association with caregiver distress. Alzheimer Dis Assoc Disord 1997; 11(suppl 4):S35-S38
20. Teri L, Gibbons LE, McCurry SM, et al: Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 2003; 290:2015-2022
21. Garre-Olmo J, Lopez-Pousa S, Vilalta-Franch J, et al: Carer's burden and depressive symptoms in patients with Alzheimer's disease. State after twelve months. Rev Neurol 2002; 34:601-607
22. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
23. Alzheimer's Association: Research consent for cognitively impaired adults: recommendations for institutional review boards and investigators. Alzheimer Dis Assoc Disord 2004; 18:171-175
24. Martin BK, Frangakis CE, Rosenberg PB, et al: Design of depression in Alzheimer's disease study-2. Am J Geriatr Psychiatry 2006; 14:920-930
25. Schneider LS, Olin JT, Doody RS, et al: Validity and reliability of the Alzheimer's Disease Cooperative Study-clinical global impression of change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S22-S32
26. Alexopoulos GS, Abrams RC, Young RC, et al: Cornell Scale for Depression in Dementia. Biol Psychiatry 1988; 23:271-284
27. Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979; 86:420-428
28. Food and Drug Administration: Food and Drug Administration, code of federal regulations title 21, section 310, Part D [online]. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfcfr/CFRSearch.cfm?FR = 310.305. Accessed June 6, 2009
29. Mace NL, Rabins PV: The 36-Hour Day: A Family Guide to Caring for Persons with Alzheimer Disease, Related Dementing Illness, and Memory Loss in Later Life. Baltimore, Johns Hopkins University Press, 2000
30. Rabins PV, Lyketsos CG, Steele C: Practical Dementia Care. New York, Oxford University Press, 1999
31. Rubin DB: Multiple Imputation for Nonresponse in Surveys. New York, John Wiley, 1996
32. Rubin DB: Multiple imputation after 18+ years. J Am Stat Assoc 1996; 91:473-489
33. Development Core Team, R: A language and environment for statistical computing. [online]. Available at: http://www.R-project.org. Accessed June 6, 2009
34. Haro M, Rubio M, Xifre B, et al: Acute eosinophilic pneumonia associated to sertraline. Med Clin (Barc) 2002; 119:637-638